US 12,440,576 B2
Antibody drug conjugates comprising sting agonists
Jeremy R. Duvall, Topsfield, MA (US); Keith W. Bentley, Boston, MA (US); Raghida A. Bukhalid, Medford, MA (US); Naniye Cetinbas, Somerville, MA (US); Marc I. Damelin, Needham, MA (US); Eugene W. Kelleher, Wellesley, MA (US); Timothy B. Lowinger, Carlisle, MA (US); Joshua D. Thomas, Natick, MA (US); Dorin Toader, Cambridge, MA (US); Ling Xu, Brookline, MA (US); and Liping Yang, Arlington, MA (US)
Assigned to Mersana Therapeutics, Inc., Cambridge, MA (US)
Filed by Mersana Therapeutics, Inc., Cambridge, MA (US)
Filed on Dec. 19, 2022, as Appl. No. 18/068,476.
Application 18/068,476 is a continuation of application No. 17/221,341, filed on Apr. 2, 2021.
Claims priority of provisional application 63/111,820, filed on Nov. 10, 2020.
Claims priority of provisional application 63/040,755, filed on Jun. 18, 2020.
Claims priority of provisional application 63/004,108, filed on Apr. 2, 2020.
Prior Publication US 2023/0321048 A1, Oct. 12, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/68 (2017.01); A61K 31/4184 (2006.01); A61K 31/422 (2006.01); A61K 31/428 (2006.01); A61K 31/437 (2006.01); A61K 45/06 (2006.01); A61K 47/54 (2017.01); A61K 47/55 (2017.01); A61K 47/60 (2017.01); A61K 47/65 (2017.01); A61P 35/00 (2006.01)
CPC A61K 47/6849 (2017.08) [A61K 31/4184 (2013.01); A61K 31/422 (2013.01); A61K 31/428 (2013.01); A61K 31/437 (2013.01); A61K 45/06 (2013.01); A61K 47/54 (2017.08); A61K 47/542 (2017.08); A61K 47/545 (2017.08); A61K 47/55 (2017.08); A61K 47/60 (2017.08); A61K 47/65 (2017.08); A61K 47/6803 (2017.08); A61K 47/6841 (2017.08); A61P 35/00 (2018.01)] 20 Claims
 
1. An antibody-drug conjugate (ADC) being

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein the HER2 antibody comprises a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence FTFSSYSMN (SEQ ID NO: 20); a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence YISSSSSTIYYADSVKG (SEQ ID NO: 21); a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence GGHGYFDL (SEQ ID NO: 22); a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence RASQSVSSSYLA (SEQ ID NO: 27); a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence GASSRAT (SEQ ID NO: 28); and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYHHSPLT (SEQ ID NO: 29), and d15 represents an integer ranging from about 1 to about 20.